Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Three ...

Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales. Read why I rate KRYS ...

IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. Vertex has had a ...

alvelestat for the treatment of severe Alpha-1 antitrypsin deficiency (AATD), which is being investigated in an ongoing Phase ...

Geode Capital Management LLC boosted its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 4.5% during the third quarter, according to the company in its most recent filing with the ...

Exciting potential in Korro Bio, Inc.'s non-viral gene editing platform as they enter clinical trials with a strong cash ...

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat ...

Rare genetic disorders affect approximately 1 in 10 people worldwide, meaning over 350 million individuals are living with these conditions. Despite their rarity, there are over 7,000 identified rare ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Krystal Biotech (KRYS – Research Report) yesterday and set a price ...